On July 25, 2022 Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, reported that data from the company’s Phase 1 study of zanidatamab zovodotin (ZW49), an investigational novel bispecific HER2 targeted antibody-drug conjugate, were accepted for an oral presentation at the European Society for Medical Oncology Congress 2022 in Paris (Press release, Zymeworks, JUL 25, 2022, View Source [SID1234616909]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The abstract, entitled "Preliminary Results From a Phase 1 Study Using the Bispecific, Human Epidermal Growth Factor 2 (HER2)-targeting Antibody-drug Conjugate (ADC) zanidatamab zovodotin (ZW49) in Solid Cancers", will be presented by Komal Jhaveri, M.D., Medical Oncologist, Memorial Sloan Kettering Cancer Center in NYC, in a mini-oral presentation on Monday, September 12 at 5:25 pm CEST during the ESMO (Free ESMO Whitepaper) meeting being held September 9-13, 2022, at the Paris Expo Porte de Versailles in Paris, France.
"This presentation represents an important milestone for Zymeworks as the first opportunity to share clinical data from our zanidatamab zovodotin development program," said Kenneth Galbraith, Chair and CEO of Zymeworks. "We are especially pleased to present these data at ESMO (Free ESMO Whitepaper), which provides us an opportunity to update many of the global leaders in cancer research from around the world on this important effort."
Zymeworks will host a conference call to further discuss the clinical data presented at ESMO (Free ESMO Whitepaper) and provide an overview on future clinical development plans for zanidatamab zovodotin after the presentation.